BioCentury | Nov 25, 2013
Product Development

Golden State IRB

...Irvine, Los Angeles and San Diego, Stanford University , the University of Southern California , Children's Hospital & Research Center Oakland...
...Center , San Francisco, Calif. Cancer Prevention & Research Institute of Texas (CPRIT), Austin, Texas Children's Hospital & Research Center Oakland...
BioCentury | Mar 18, 2013
Company News

Bayer, Children's Hospital & Research Center Oakland deal

...research efforts. The hospital could not be reached for details. Bayer AG (Xetra:BAYN), Leverkusen, Germany Children's Hospital & Research Center Oakland...
BioCentury | May 24, 2010
Clinical News

Trappsol hydroxypropyl-beta-cyclodextrin regulatory update

FDA granted Orphan Drug designation to the hospital for Trappsol hydroxypropyl-beta-cyclodextrin (HPBCD) to treat Niemann-Pick type C disease. Children's Hospital & Research Center , Oakland, Calif. Product: Trappsol hydroxypropyl-beta-cyclodextrin ( HPBCD ) Business: Metabolic WIR Staff...
BioCentury | Jan 17, 2005
Company News

BioVeris, Children's Hospital & Research Center deal

The hospital granted BIOV an option to exclusively license a vaccine against Neisseria meningitidis serogroup B. If BIOV exercises its option, the hospital will receive a license fee and potential milestones and royalties. Also, BIOV...
Items per page:
1 - 4 of 4
BioCentury | Nov 25, 2013
Product Development

Golden State IRB

...Irvine, Los Angeles and San Diego, Stanford University , the University of Southern California , Children's Hospital & Research Center Oakland...
...Center , San Francisco, Calif. Cancer Prevention & Research Institute of Texas (CPRIT), Austin, Texas Children's Hospital & Research Center Oakland...
BioCentury | Mar 18, 2013
Company News

Bayer, Children's Hospital & Research Center Oakland deal

...research efforts. The hospital could not be reached for details. Bayer AG (Xetra:BAYN), Leverkusen, Germany Children's Hospital & Research Center Oakland...
BioCentury | May 24, 2010
Clinical News

Trappsol hydroxypropyl-beta-cyclodextrin regulatory update

FDA granted Orphan Drug designation to the hospital for Trappsol hydroxypropyl-beta-cyclodextrin (HPBCD) to treat Niemann-Pick type C disease. Children's Hospital & Research Center , Oakland, Calif. Product: Trappsol hydroxypropyl-beta-cyclodextrin ( HPBCD ) Business: Metabolic WIR Staff...
BioCentury | Jan 17, 2005
Company News

BioVeris, Children's Hospital & Research Center deal

The hospital granted BIOV an option to exclusively license a vaccine against Neisseria meningitidis serogroup B. If BIOV exercises its option, the hospital will receive a license fee and potential milestones and royalties. Also, BIOV...
Items per page:
1 - 4 of 4